MedTrace Logo

Norfloxacin With Itopride Versus Norfloxacin in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

NCT04161768 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2019-11-13

No results posted yet for this study

Summary

Norfloxacin versus Norfloxacin with Itopride in Secondary Prophylaxis of Spontaneous Bacterial Peritonitis

Conditions

  • Spontaneous Bacterial Peritonitis

Interventions

DRUG

Norfloxacin

Norfloxacin 400 mg daily

DRUG

Itopride

Itopride 50 mg three times daily

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Afaf Younes Mohammed Younes, Msc · Tanta University - Faculty of Medicine

  • Mona Ahmed Helmy Shehata, Prof. · Tanta University - Faculty of Medicine

  • Sherief Abd-Elsalam, Ass. Prof. · Tanta University - Tropical Medicine Department

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-01
Primary Completion
2028-12-01
Completion
2028-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161768 on ClinicalTrials.gov